
The Curious Case of MacroGenics: A Cautionary Tale for Investors
MacroGenics’ stock has plummeted 85% over the past year, highlighting the volatile nature of biotech investments. Despite reporting a 17% increase in revenue, the market remains skeptical, contributing to a recent 26% share price decline in three months. The company faces challenges